RxDoctor Payments Data

Brenda Hampton, MD

Family Medicine · Garland, TXNPI 1326021072

Payments from drug & device makers

$407in general payments, 2019–2025

Across 34 payments — averaging $11.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$159
  • AstraZeneca$54
  • Lilly USA, LLC$50
  • AbbVie$30
  • Amarin Pharma, Inc.$28
  • Astellas Pharma US Inc$22
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$38996%
  • Gifts$184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk17$159
AstraZeneca4$54
Lilly USA, LLC4$50
AbbVie2$30
Amarin Pharma, Inc.2$28
Astellas Pharma US Inc1$22
Eisai Inc.1$18
Ascend Therapeutics US, LLC1$18
Teva Pharmaceuticals USA, Inc.1$15
Merck1$13

How this compares

$407 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$54,048
Medicare patients
117
Services billed
1,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide65$68,408
OzempicSemaglutide30$26,424
Synjardy XrEmpagliflozin/Metformin Hcl17$22,994
JardianceEmpagliflozin18$16,223
RexultiBrexpiprazole11$15,243
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,399
Arnuity ElliptaFluticasone Furoate11$3,710
Icosapent Ethyl12$3,510
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,054
SynthroidLevothyroxine Sodium27$2,496
Montelukast Sodium142$2,076
Estradiol32$2,057
Duloxetine Hcl51$1,674
Humalog Kwikpen U-100Insulin Lispro11$1,661
Gabapentin121$1,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$50$68,40865 claims
Novo NordiskOzempic$159$26,42430 claims
AbbVieSynthroid$30$2,49627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Garland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →